SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII)
NTII 0.00Dec 18 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (333)4/20/1998 11:12:00 AM
From: John Dwyer  Read Replies (2) of 1494
 
Thanks Peter,

If Merz is going to conduct the Phase III, then all NTII
has to do is survive the Phase IIb trials. If they do, then
I would expect the clouds to start lifting for NTII stock. I
agree that Merz probably has good Phase III data and that approval
(at least for some indications) is likely. Getting the license
from Children's probably clears the way for a Merz-sponsered
clinical trial of Memantine in the US for several indications. How
quickly can NTII finish the Phase II? Maybe by Feb 1999?

As for listing, I doubt they are even close to meeting the
requirements. I believe that the average stock price needs to
be over a dollar for some period of time (30 days??). Their
financial picture has improved only to where they were late
last summer and they were in violation at that time. I'm not
sure what the exact requirements are, however. If they get
re-listed, that would really change the picture since many money
managers have restrictions on buying stocks that have been
de-listed.

John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News